<SEC-DOCUMENT>0001553350-20-000215.txt : 20200313
<SEC-HEADER>0001553350-20-000215.hdr.sgml : 20200313
<ACCEPTANCE-DATETIME>20200313092356
ACCESSION NUMBER:		0001553350-20-000215
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20200310
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200313
DATE AS OF CHANGE:		20200313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HEAT BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001476963
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262844103
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35994
		FILM NUMBER:		20710915

	BUSINESS ADDRESS:	
		STREET 1:		627 DAVIS DRIVE
		STREET 2:		SUITE 400
		CITY:			MORRISVILLE
		STATE:			NC
		ZIP:			27560
		BUSINESS PHONE:		919-240-7133

	MAIL ADDRESS:	
		STREET 1:		627 DAVIS DRIVE
		STREET 2:		SUITE 400
		CITY:			MORRISVILLE
		STATE:			NC
		ZIP:			27560
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htbx_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Current Report</TITLE>
<META NAME="author" CONTENT="Patrick Egan">
<META NAME="date" CONTENT="03/13/2020">
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<P style="margin-top:0px; margin-bottom:9.8px; font-family:Calibri,Times New Roman; font-size:11pt">&nbsp;</P>
<P style="margin-top:0px; margin-bottom:9.8px"><BR></P>
<P style="line-height:1pt; margin:0px; font-size:11pt">&nbsp;<FONT style="font-size:10pt">&nbsp;</FONT></P>
<P style="margin-top:0px; margin-bottom:2.267px; padding-bottom:4px; font-family:Calibri,Times New Roman; font-size:11pt; border-bottom:4px solid #000000" align=right>&nbsp;</P>
<P style="margin-top:0px; margin-bottom:9px; padding-top:4px; font-family:Calibri,Times New Roman; font-size:11pt; border-top:1.333px solid #000000" align=right>&nbsp;</P>
<P style="margin:0px" align=center><B>UNITED STATES</B></P>
<P style="margin:0px" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0px" align=center><B>WASHINGTON, D.C. 20549</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>FORM 8-K</B></P>
<P style="margin:0px" align=center>&nbsp;</P>
<P style="margin:0px" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center>Date of Report (date of earliest event reported): <B>March 10, 2020</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:14pt" align=center><B>Heat Biologics, Inc.</B></P>
<P style="margin:0px; font-size:8pt" align=center><I>(Exact name of registrant as specified in charter)</I></P>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A><P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>Delaware</B></P>
<P style="margin:0px; font-size:8pt" align=center><I>(State or other jurisdiction of incorporation)</I></P>
<P style="margin:0px" align=center>&nbsp;</P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 align=center><TR height=0 style="font-size:0"><TD width=322 /><TD width=322 /></TR>
<TR><TD style="margin-top:0px" valign=top width=322><P style="margin:0px" align=center><B>001-35994</B></P>
</TD><TD style="margin-top:0px" valign=top width=322><P style="margin:0px" align=center><B>26-2844103</B></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=322><P style="margin:0px; font-size:8pt" align=center><I>(Commission File Number)</I></P>
</TD><TD style="margin-top:0px" valign=top width=322><P style="margin:0px; font-size:8pt" align=center><I>(IRS Employer Identification No.)</I></P>
</TD></TR>
</TABLE>
<P style="line-height:10pt; margin:0px"><BR></P>
<P style="line-height:11pt; margin:0px" align=center><B>627 Davis Drive, Suite 400</B></P>
<P style="margin:0px" align=center><B>Morrisville, North Carolina 27560</B></P>
<P style="margin:0px; font-size:8pt" align=center><I>&nbsp;(Address of principal executive offices and zip code)</I></P>
<P style="line-height:10pt; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>(919) 240-7133</B></P>
<P style="margin:0px; font-size:8pt" align=center><I>(Registrant&#146;s telephone number including area code)</I></P>
<P style="line-height:10pt; margin:0px">&nbsp;</P>
<P style="margin:0px" align=center><B>N/A</B></P>
<P style="margin:0px; font-size:8pt" align=center><I>(Former Name and Former Address)</I></P>
<P style="line-height:10pt; margin:0px"><BR></P>
<P style="margin:0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>
<P style="line-height:10pt; margin:0px">&nbsp;</P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD width=43 /><TD width=29 /><TD /></TR>
<TR><TD style="margin-top:0px" valign=top width=43><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=29><P style="margin:0px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=43><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=29><P style="margin:0px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=43><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=29><P style="margin:0px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=43><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=29><P style="margin:0px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
</TD></TR>
</TABLE>
<P style="line-height:10pt; margin:0px"><BR></P>
<P style="margin:0px">Securities registered pursuant to Section 12(b) of the Act:</P>
<P style="line-height:10pt; margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 align=center><TR height=0 style="font-size:0"><TD width=258 /><TD width=143 /><TD width=282 /></TR>
<TR><TD style="margin-top:0px; border:1px solid #000000" valign=top width=258><P style="margin:0px; font-size:8pt" align=center><B>Title of each class</B></P>
</TD><TD style="margin-top:0px; border-top:1px solid #000000; border-right:1px solid #000000; border-bottom:1px solid #000000" valign=top width=143><P style="margin:0px; font-size:8pt" align=center><B>Trading Symbol(s)</B></P>
</TD><TD style="margin-top:0px; border-top:1px solid #000000; border-right:1px solid #000000; border-bottom:1px solid #000000" valign=top width=282><P style="margin:0px; font-size:8pt" align=center><B>Name of each exchange on which registered</B></P>
</TD></TR>
<TR><TD style="margin-top:0px; border-left:1px solid #000000; border-right:1px solid #000000; border-bottom:1px solid #000000" valign=top width=258><P style="margin:0px" align=center>Common Stock, $0.0002 par value per share</P>
</TD><TD style="margin-top:0px; border-right:1px solid #000000; border-bottom:1px solid #000000" valign=top width=143><P style="margin:0px" align=center>HTBX</P>
</TD><TD style="margin-top:0px; border-right:1px solid #000000; border-bottom:1px solid #000000" valign=top width=282><P style="margin:0px" align=center>The Nasdaq Capital Market</P>
</TD></TR>
</TABLE>
<P style="line-height:8pt; margin:0px"><BR></P>
<P style="margin:0px" align=justify>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</P>
<P style="line-height:10pt; margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=320 /><TD width=320 /></TR>
<TR><TD style="margin-top:0px" valign=top width=320><P style="margin:0px; text-indent:48px">Emerging growth company&nbsp; <FONT style="font-family:Wingdings">&#168;</FONT></P>
</TD><TD style="margin-top:0px" valign=top width=320><P style="margin:0px">&nbsp;</P>
</TD></TR>
</TABLE>
<P style="line-height:10pt; margin:0px"><BR></P>
<P style="margin:0px" align=justify>If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;<FONT style="font-family:Wingdings">&#168;</FONT></P>
<P style="margin-top:0px; margin-bottom:2.467px; padding-bottom:4px; font-family:Calibri,Times New Roman; font-size:11pt; border-bottom:1.333px solid #000000">&nbsp;</P>
<P style="margin-top:0px; margin-bottom:9.8px; padding-top:4px; font-family:Calibri,Times New Roman; font-size:11pt; border-top:4px solid #000000">&nbsp;</P>
<A NAME="FIS_SECTION_1_BUSINESS_AND_OPERATIONS"></A><A NAME="FIS_ENTRY_MATERIAL_AGREEMENT"></A><P style="margin-top:0px; margin-bottom:8.867px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<HR style="margin-bottom:9.6px; padding-top:9.6px" noshade size=1.333>
<P style="margin-top:0px; margin-bottom:9.8px; font-family:Calibri,Times New Roman; font-size:11pt; page-break-before:always">&nbsp;</P>
<P style="margin-top:0px; margin-bottom:9.8px"><BR></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><B>Item 1.01. &nbsp;&nbsp;Entry Into A Material Definitive Agreement.</B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>On March 10, 2020,<B> </B>Heat Biologics, Inc. (the <font style='font-family:Arial Unicode MS,Times New Roman'>&#8220;</font>Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8221;</font>) entered into Amendment No. 2 dated March 10, 2020 (<font style='font-family:Arial Unicode MS,Times New Roman'>&#8220;</font>Amendment No. 2<font style='font-family:Arial Unicode MS,Times New Roman'>&#8221;</font>) to the Rights Agreement dated March 11, 2018, as amended by Amendment No. 1 thereto (&#147;Amendment No. 1&#148;) dated March 8, 2019 (the &#147; Rights Agreement&#148;) by and between the Company and Continental Stock Transfer &amp; Trust Company, as rights agent. Under the terms of Amendment No. 2, the expiration date of the Company&#146;s stockholder rights plan has been extended to March 11, 2021, or such earlier date that the Company redeems or exchanges the rights as described in the Rights Agreement. </P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>A copy of Amendment No. 2 is included as Exhibit 4.3 to this Current Report on Form 8-K and is incorporated by reference herein. &nbsp;&nbsp;A copy of the Rights Agreement as originally executed is included as Exhibit 4.1 to this Current Report on Form 8-K and Amendment No. 1 is included as Exhibit 4.2 to this Current Report on Form 8-K and such agreements are incorporated herein by reference. The foregoing summary of Amendment No. 2 and the Rights Agreement are qualified in their entirety by reference to Exhibits 4.1, 4.2 and 4.3.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px"><B>Item 3.03. &nbsp;&nbsp;Material Modification to Rights of Security Holders.</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=justify>The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated<B> </B>into this Item 3.03 by reference.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=justify><B>Item 5.02.</B> &nbsp;&nbsp;<B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>On March 12, 2020, the Board of Directors (the &#147;Board&#148;) of the Company granted two executive officers of the Company, Dr. Jeff Hutchins, Chief Scientific Officer and Chief Operating Officer of the Company, and William Ostrander, Vice President of Finance of the Company, the following equity-based awards: (i) Dr. Hutchins was awarded a stock option to purchase 500,000 shares of the Company&#146;s common stock, and (ii) Mr. Ostrander was awarded a stock option to purchase 150,000 shares of the Company&#146;s common stock. The stock option awards vest pro rata on a monthly basis over 48 months commencing on April 1, 2020, subject to the officer&#146;s continuous service to the Company on each applicable vesting date. The options are exercisable for a period of ten years from the date of grant and have an exercise price of $0.60 per share. </P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><B>Item 9.01. &nbsp;&nbsp;Financial Statements and Exhibits.</B></P>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD /></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px">(d) Exhibits.</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px">The following exhibits are filed with this Current Report on Form 8-K:</P>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD width=52 /><TD width=14 /><TD /></TR>
<TR><TD style="margin-top:0px; border-bottom:1px solid #000000" valign=bottom width=52><P style="margin:0px; font-size:8pt" align=center><B>Exhibit Number</B></P>
</TD><TD style="margin-top:0px" valign=bottom width=14><P style="margin:0px; font-size:8pt">&nbsp;</P>
</TD><TD style="margin-top:0px; border-bottom:1px solid #000000" valign=bottom><P style="margin:0px; font-size:8pt"><B>Description</B></P>
</TD></TR>
<TR><TD style="margin-top:0px; background-color:#CCFFCC" valign=top width=52><P style="margin:0px" align=center>4.1</P>
</TD><TD style="margin-top:0px; background-color:#CCFFCC" valign=top width=14><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px; background-color:#CCFFCC" valign=top><P style="margin:0px"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335018000199/htbx_ex4z1.htm">Rights Agreement dated as of March 11, 2018 by and between Heat Biologics, Inc. and Continental Stock Transfer &amp; Trust Company, as rights agent (incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2018 (File No. 001-35994)</A>)</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=52><P style="margin:0px" align=center>4.2</P>
</TD><TD style="margin-top:0px" valign=top width=14><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335019000202/htbx_ex4z2.htm">Amendment No. 1 to the Rights Agreement dated as of March 8, 2019 to the Rights Agreement dated March 11, 2018 by and between Heat Biologics, Inc. and Continental Stock Transfer &amp; Trust Company, as rights agent (incorporated by reference to t<FONT style="font-size:11pt">he</FONT><FONT style="font-family:Calibri,Times New Roman; font-size:11pt"> </FONT>Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2019 (File No. 001-35994)</A>)</P>
</TD></TR>
<TR><TD style="margin-top:0px; background-color:#CCFFCC" valign=top width=52><P style="margin:0px" align=center>4.3</P>
</TD><TD style="margin-top:0px; background-color:#CCFFCC" valign=top width=14><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px; background-color:#CCFFCC" valign=top><P style="margin:0px; color:#0000FF"><A HREF="http://www.sec.gov/Archives/edgar/data/1476963/000155335020000213/htbx_ex4z3.htm"><U>Amendment No. 2 to the Rights Agreement dated as of March 10, 2020 to the Rights Agreement dated March 11, 2018, as amended by Amendment No. 1 thereto, dated as of March 8, 2019, by and between Heat Biologics, Inc. and Continental Stock Transfer &amp; Trust Company, as rights agent (incorporated by reference to the Registration Statement on Form 8-A/A filed with the Securities and Exchange Commission on March 13, 2020 (File No. 001-35994))</U></A><FONT style="color:#000000"></FONT></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=52><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=14><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=top><P style="margin:0px; padding:0px">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin-top:0px; margin-bottom:13.333px"><BR></P>
<A NAME="eolPage5"></A><A NAME="FIS_SIGNATURES"></A><P style="margin:0px" align=center><BR>
<BR></P>
<HR style="margin-bottom:9.6px; padding-top:9.6px" noshade size=1.333>
<P style="margin-top:0px; margin-bottom:9.8px; font-family:Calibri,Times New Roman; font-size:11pt; page-break-before:always">&nbsp;</P>
<P style="margin-top:0px; margin-bottom:9.8px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><B>SIGNATURES</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD /><TD width=49 /><TD width=245 /></TR>
<TR><TD style="margin-top:0px"><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" width=49><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" width=245><P style="margin:0px; padding:0px">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px">Dated:&nbsp;&nbsp;March 13, 2020</P>
</TD><TD style="margin-top:0px" valign=top width=294 colspan=2><P style="margin:0px">HEAT BIOLOGICS, INC.</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=294 colspan=2><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=49><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=245><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=49><P style="margin:0px">By:</P>
</TD><TD style="margin-top:0px; border-bottom:1px solid #000000" valign=top width=245><P style="margin:0px">/s/ Jeffrey Wolf</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=49><P style="margin:0px">Name:</P>
</TD><TD style="margin-top:0px" valign=top width=245><P style="margin:0px">Jeffrey Wolf</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=49><P style="margin:0px">Title:</P>
</TD><TD style="margin-top:0px" valign=top width=245><P style="margin:0px">Chairman, President and<BR>
Chief Executive Officer</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
</BODY>
<!-- EDGAR Validation Code: 3EE9EF6A -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
